Global team of seasoned early stage investors, former entrepreneurs, and subject matter experts.

Investment team


Cornel Chiriac // Partner // London, UK

Cornel is the founding partner of 2050 Capital, syndicate lead and early stage venture investor. Cornel focuses on enterprise software and biotech. Among other deals, Cornel led the seed investment rounds in AMFG (digital factory software), Grakn (knowledge graph database), and Origin Sciences (DNA sequencing cancer diagnostics). Cornel serves on several boards and advisory committees, and in one instance served as interim-CEO and delivered a turnaround, grew revenues 10x, and reached profitability within 9 months.

Complementary to 2050 Cap, Cornel heads the Chicago Booth Angels London chapter, was instrumental to scaling the investment group globally, and is involved with various University of Chicago venture initiatives.

In his earlier career Cornel built and scaled two entrepreneurship ventures in the USA to multi-million exits, was a strategy and deal consultant with L.E.K. in London, and a corporate VC with the World Gold Council. Cornel remains involved with Fieldstone Capital as a director and head of energy technology ventures. Prior to settling in London, Cornel lived and worked in the USA for over a decade and in China & South-East Asia for four years.

Cornel holds a MBA from the University of Chicago Booth School of Business.


Alex Lintott // Partner // Austin, TX, USA

Alex is a partner at 2050 Capital and an active early stage venture investor.

Alex is a seasoned operator and investor, with a strong finance and accounting background. Currently based in Texas, he has worked in North America, Europe, and South America. Prior to 2050 Cap, Alex served as CEO of a manufacturing and media services company for 4 years. This company was acquired by a private investment fund he created and led to find, acquire, and operate a single company on behalf of both private and institutional investors (i.e., a search fund). Earlier in his career, Alex worked with Chevron in a variety of operational, strategy, commercial, and business development roles, and with both Lazard Frères and Merrill Lynch in New York as an investment banker. Alex began his career in public accounting at Deloitte, and is a Certified Public Accountant.   

Complementary to 2050 Cap, Alex also is a founding member and heads the Chicago Booth Angels Texas chapter.

Alex holds a MBA from the University of Chicago Booth School of Business, and both a masters and bachelors degree in accounting from the University of Texas at Austin.


Fernand Lendoye // Partner // Singapore

Fernand is an angel investor and partner at 2050 Capital. He focuses on healthcare, fintech and insuretech.

Additionally, Fernand is the Co-Founder & Managing Director at Brightriver Capital – a private equity fund investing in a variety of sectors across Southeast Asia. Prior to founding Brightriver, Fernand was the MD of Aviva Ventures, where he focused on healthcare, fintech / insure tech, and mobility. 

Fernand is a seasoned financial services executive. He has worked in Asia, Europe and North America. Before Aviva Ventures, he gained global transactional and operating experience in shaping growth strategies and business development, opening new markets and driving business turnaround. His broad transactional experience ranges from a £5 billion+ transformative acquisition in the UK to a $20 billion+ IPO in Asia. 

Fernand holds a MBA from the University of Chicago Booth School of Business.


Brian Sohn // Partner // South Korea

Brian is an angel investor and partner at 2050 Capital. He focuses on the firm’s activities in South Korea.

Brian’s early stage investment experience includes venture capital investments for Korean-based Gisson Capital and leading venture syndicates with Startup Research. Brian is an experienced CFO and often provides financial expertise to portfolio companies.

In his earlier career, Brian led investor relations for LG Electronics, was an equity research analyst with HSBC, and led the global business division for GCCEI (focused on IoT, 5G, ICT, gaming).

Brian holds a MBA and Finance degree from the University of Akron.




Scott F. Meadow // Senior Advisor // Chicago, IL, USA

Since 1982, Scott Meadow has been a principal investor in the venture capital industry. He is the 2011 recipient of the Richard J. Daley Award. The Daley Medal acknowledges a single individual who has given direct and extraordinary support to the state of Illinois by participating in or being an advocate for the venture capital and private equity industry.

Professor Meadow has held the position of Clinical Professor of Entrepreneurship at the University of Chicago Booth School of Business since 2000 and has taught over 10,000 students. He is the faculty advisor for the Venture Capital Investment Competition and is also on the Advisory Board and Steering Committee of the Innovation Fund at the University of Chicago.

Scott has over 30 years’ experience as a general partner with four venture capital and private equity firms including William Blair Venture Partners, The Frontenac Company, The Sprout Group, and most recently with the Edgewater Funds, where he remains an Associate Partner. Over the course of his career, Scott has approved hundreds of equity financings, been active in fundraising and has personally led, originated or created more than sixty investments including two dozen healthcare services companies, over a dozen consumer services and retail companies, as well as biotech companies and companies enhanced by the Internet and social media. Scott has been recognized by Venture One as one of the outstanding healthcare investors in the industry, and is a testifying expert witness in a broad range of commercial disputes involving entrepreneurship.

Representative investments include Coventry Corporation, HEALTHSOUTH, Sunrise Assisted Living, Sunrise International, Managed Health Network, Aspen Education Services, Seurat Therapeutics, Pathology Partners, Heritage Healthcare, MedPartners, The Sports Authority, CompUSA and Staples. Scott recently served on the board of directors of National Equipment Services (NASDAQ: NLEQ) during its emergence from Chapter 11 and Barrier Safe Systems. He has served on the Advisory Board of Invenergy, GenerationOne, Dais Corporation and Anka Associates, a private equity firm focused on Turkey.

Professor Meadow earned his A.B. Magna Cum Laude from Harvard College and his M.B.A. from Harvard Business School.


Rupert Lywood // Senior Advisor // London, UK

Rupert has spent 25 years founding and building businesses in the medical, energy, information, finance, and media sectors – including co-founding and chairing a multi-billion trans-European energy business, sold in 2007. Over his career Rupert has helped create over 40 start-ups, many of which have become large businesses, and he remains active in all these sectors.

Rupert is a chartered accountant who qualified with Robson Rhodes. Latterly he specialised in structured finance and venture capital.

Rupert is a keen sailor. He has taken part in and completed the ARCS transatlantic race in 2009 and 2014. Rupert is also a film producer, with one of his films winning an Academy Award in 2005.


Shann Yu // Science Advisor // Chicago, IL, USA

Shann is the Scientific Director of the Chicago Immunoengineering Innovation Center (CIIC) of the University of Chicago Pritzker School of Molecular Engineering. With a research portfolio that spans immunology, bioengineering, oncology, autoimmunity, vaccines, and transplantation, and a body of entrepreneurially-minded researchers, the CIIC actively seeks to maximize the impact of its discoveries through venture building, and has spun off Kanyos Bio (acquired by Anokion SA), ClostraBio, BiomeSense, Arrow Immune, HeioThera, and more. Within this organization, Shann’s roles include oversight, fundraising, and budget management for internal research and training programs, as well as bridging these programs with external partners. 

Shann earned his B.S. in bioengineering from Rice University and his M.S. and Ph.D. in biomedical engineering from Vanderbilt University. He pursued postdoctoral training in immunology and lymphatic biology at the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL) and the University of Chicago, prior to transitioning to his current role.